★ Island Care, World-Class Orthopedics · A full-service orthopedic group · Oahu & Big Island News Careers Contact Patient Portal (808) 439-6201

Published

Beyond Platelets: What Concentrated Platelet-Poor Plasma Contains

Beyond Platelets: What Concentrated Platelet-Poor Plasma Contains

Platelet-poor plasma (PPP) is not protein-free. The liquid component of blood contains many proteins, even after most platelets have been separated into the platelet-rich plasma (PRP) fraction. Researchers are investigating whether selected proteins from PPP can be concentrated for orthopedic applications. However, finding a protein in a preparation, measuring its concentration, and proving patient benefit are three different steps.

PPP vs. PRP: what is different?

PRP is prepared to contain more platelets than ordinary blood, while PPP contains comparatively few platelets. Both fractions contain plasma molecules. Neither term defines an identical product across every system: the amount of blood drawn, centrifugation method, handling, and filtration affect the final mixture. A given PPP sample should not be assumed to contain a predictable amount of each protein without measurement.

PRP is studied for conditions such as knee osteoarthritis and some tendon problems. PPP-based preparations are a separate scientific question, not an automatically better form of PRP. Learn more about PRP injections at Pacific Bone & Joint.

How does protein concentration from PPP work?

Some methods use ultrafiltration, passing part of the fluid through a membrane while retaining selected larger molecules. The reduced volume may increase the concentration of proteins that remain. This process is different from using a centrifuge to select more platelets.

In a 2025 study of PPP ultrafiltration, investigators worked with blood from ten donors. In that particular process, the PPP volume was reduced from about 60 to 12 milliliters. Mean measured alpha-2-macroglobulin (A2M) concentration increased from approximately 1.62 to 6.66 mg/mL, and insulin-like growth factor 1 (IGF-1) rose from about 69 to 258 ng/mL.

Those numbers are laboratory measurements using one method, not measured results from Pacific Bone & Joint or a guarantee that another device will produce the same concentrations. Some proteins are more readily retained than others, and filtration can cause losses or changes in biologic activity. Reducing volume fivefold does not establish fivefold enrichment of every protein, much less fivefold clinical benefit.

Which additional proteins are found in plasma?

A2M: a protease inhibitor

Alpha-2-macroglobulin (A2M) is a large plasma protein that can bind and inhibit certain protein-degrading enzymes. Researchers are interested in its potential to affect biochemical pathways involved in joint tissue breakdown. Its presence in a blood product does not mean it can reverse cartilage loss in people.

IGF-1: an important growth signal

Insulin-like growth factor 1 (IGF-1) participates in growth and cellular signaling, often circulating alongside binding proteins. Its concentration can be measured in certain PPP fractions. This is a biological observation, not proof that an IGF-1-containing injection regenerates cartilage or helps patients walk farther.

HGF: a plasma-associated signaling protein

Hepatocyte growth factor (HGF) participates in multiple tissue-signaling pathways and can be present in blood-derived materials. Whether a specific filter retains HGF, and how much active HGF remains, require product-specific measurements. The presence of HGF in plasma does not demonstrate clinical effectiveness.

Fibrinogen and fibronectin: clot and matrix proteins

Fibrinogen contributes to blood clotting and can form fibrin. Fibronectin helps cells interact with extracellular matrix structures. Both are relevant to normal plasma and tissue biology, but their recovery after concentration depends on how the product is made and whether clotting has occurred.

Albumin: a common carrier protein

Albumin is abundant in plasma and helps maintain fluid balance while carrying other molecules. Its inclusion is not inherently evidence of anti-inflammatory or cartilage-restoring activity. More total protein is not necessarily better treatment.

What about IL-1Ra and soluble inflammatory receptors?

Some discussions of blood-derived injections include IL-1 receptor antagonist (IL-1Ra) and soluble receptors involved in inflammatory signaling. A study of autologous protein solution (APS) prepared from blood of patients with osteoarthritis measured elevated concentrations of several such proteins in that particular preparation.

APS is not the same as a generic concentrated PPP product. An assay performed on one processing system cannot be presented as the expected composition of a different system. Likewise, demonstrating a favorable anti-inflammatory protein profile does not, by itself, establish that patients will have durable pain relief.

Does concentrating A2M or IGF-1 improve osteoarthritis?

We do not yet have compelling evidence that simply concentrating these proteins from PPP improves patient outcomes or restores cartilage.

In a 2024 randomized clinical trial, 75 patients with mild-to-moderate knee osteoarthritis received A2M-rich concentrate, conventional PRP, or a corticosteroid injection. At 12 weeks, changes in patient-reported outcomes were not significantly different across treatment groups, although some measures improved within groups. The authors did not establish superior short-term effectiveness for the A2M intervention.

The study does not rule out every future formulation. It does demonstrate the importance of controlled human trials rather than relying solely on a plausible laboratory mechanism. Different diagnoses, doses, processing methods, and follow-up times require study.

For context, conventional PRP evidence for knee arthritis is also mixed. In the RESTORE placebo-controlled trial, knee pain and cartilage-volume outcomes at one year were not significantly improved compared with saline. Patients should be cautious about any claim that a blood-derived injection will predictably regrow cartilage, cure arthritis, or eliminate the need for joint replacement.

What questions should patients ask about PPP proteins?

Before choosing an injection based on a claim about “concentrated proteins,” consider these questions:

  1. What exact preparation is being used? Is it ordinary PRP, PPP, ultrafiltered PPP, or a specific APS product? These are not interchangeable.
  2. Which molecules have actually been measured? Ask whether A2M, IGF-1, HGF, albumin, fibrinogen, or relevant cytokines were assayed in the final product, or whether concentration is only estimated.
  3. What human study supports its use for my diagnosis? A laboratory increase in protein concentration is not the same as demonstrable improvement in knee pain, tendon function, or joint structure.
  4. What are the alternatives and risks? Discuss rehabilitation, medications, image-guided injections when appropriate, other nonsurgical options, and surgery if indicated. Blood-derived injections still involve potential discomfort, swelling, bleeding, and uncommon infection.

A careful clinician should discuss realistic goals and how improvement will be measured, rather than guarantee outcomes. To compare provider qualifications, total platelet dose, and injection guidance, see our separate article on how to choose a PRP provider in Hawaii.

Considering a biologic injection in Hawaii?

The science of plasma proteins is evolving. A2M and IGF-1 are scientifically interesting, but no universal ideal PPP protein formula has been proven for routine orthopedic care. Any proposed treatment should be matched to the diagnosis, available evidence, the patient’s goals, and a safe plan for follow-up.

At Pacific Bone & Joint, the appropriate starting point is an orthopedic evaluation—not a promise about a laboratory concentration. Request a consultation to discuss whether PRP, a rehabilitation program, other injections, or a different treatment best fits your situation.

Sources and further reading

General patient education only, not individualized medical advice. This article does not claim that Pacific Bone & Joint assays, concentrates, or routinely uses a particular PPP protein product.

Dr. Paul Norio Morton, MDWritten and edited by Paul Norio Morton, MD, FAAOS, FAAHKS  ·  Board-certified orthopedic surgeon · Updated October 21, 2026

This article is educational and is not a substitute for medical advice. Individual results vary.

Questions about your care?

Schedule Appointment → Call (808) 439-6201

Many orthopedic problems improve with physical therapy alone. Learn about PB&J Physical Therapy · Find care near you

Call Schedule Appointment